Skip to content

Effects of Resistance and Endurance Training in Pediatric Cancer Patients During Intensive Treatment Phase

Effects of Combined Resistance and Endurance Training in Pediatric Cancer Patients During Intensive Treatment Phase

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02612025
Acronym
MUCKI
Enrollment
35
Registered
2015-11-23
Start date
2015-11-30
Completion date
2018-09-30
Last updated
2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Oncology

Brief summary

The purpose of this study is to determine whether combined endurance and resistance training can improve muscle strength in children and adolescents with cancer during the intensive treatment phase.

Interventions

BEHAVIORALExercise Training

Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.

Sponsors

Johannes Gutenberg University Mainz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Malignant Tumor * Medical Treatment in the Center for Pediatrics, Hematology, Oncology and Hemostaseology Mainz (Germany) * \> 3 years * Signed Informed Consent

Exclusion criteria

* Functional and/or cognitive limitations which limit performance during training * Orthopedic condition which hinders to adequately participate in exercise training * Heart failure (NYHA III-IV) * Partial or global respiratory failure * Symptomatic coronary disease * Serious therapy-refractory hypertonia * Sustainable thrombocytopenia \<10.000/µl, f. ex. therapy-refractory autoimmune thrombocytopenia * Hereditary or acquired thrombocytopenia or coagulation disturbance * Uncontrolled cerebral spasm * CNS metastases * Medical or psychological condition which does in the doctors opinion not allow participation in sport activity

Design outcomes

Primary

MeasureTime frameDescription
Muscle strength: lower limbSix weeks (pre-post intervention)Lower limb muscle strength measured by the load (kg) sustained in one repetition maximum test

Secondary

MeasureTime frameDescription
Biomarker in BloodAt the beginning of the intervention and three and six weeks after the beginning. Comparing the two time points inbetween study groupsImmune status and metabolic status
Body compositionSix weeks (pre-post intervention)Bioelectrical Impedance Analysis
Six-minute-walk performanceSix weeks (pre-post intervention)
Muscle strength: upper limbSix weeks (pre-post intervention)Upper limb muscle strength measured by the load (kg) sustained in one repetition maximum test
Quality of LifeSix weeks (pre-post intervention)KINDL: health related quality of life questionnaire
Cardiorespiratory performanceSix weeks (pre-post intervention)Ergospirometry
Fatiguesix weeks (pre-post intervention)Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026